Dandona Paresh, Kumar Vikramjeet, Aljada Ahmad, Ghanim Husam, Syed Tufail, Hofmayer Debborah, Mohanty Priya, Tripathy Devjit, Garg Rajesh
Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209, USA.
J Clin Endocrinol Metab. 2003 Sep;88(9):4496-501. doi: 10.1210/jc.2002-021836.
In view of the pro-oxidant and proinflammatory effects of angiotensin II, we have tested the hypothesis that valsartan, an angiotensin receptor blocker, may exert a suppressive action on reactive oxygen species (ROS) generation, nuclear factor kappa B (NF-kappa B) in mononuclear cells. Four groups of eight normal subjects were given 1) 160 mg daily of valsartan, 2) 80 mg daily of simvastatin, 3) 40 mg quinapril, or 4) no treatment. Fasting blood samples were obtained before treatment and at d 1, 8, and 14 (7 d after the cessation of the drug). After valsartan, ROS generation by polymorphonuclear cells and mononuclear cells fell significantly by more than 40% (P < 0.01). NF-kappa B binding activity and the expression of total cellular p65, a protein component of NF-kappa B, fell significantly (P < 0.01). The expression of inhibitor kappa B (I kappa B) increased significantly (P < 0.05). Plasma C-reactive protein (CRP) concentration fell significantly (P < 0.01). All indices, except I kappa B, reverted toward baseline, 7 d after the cessation of the drug. I kappa B persisted in an elevated state. Neither quinapril nor simvastatin given for 7 d produced a suppression of ROS generation, intranuclear NF-kappa B, p65, or CRP, and these two agents did not alter cellular I kappa B either. The untreated controls also did not demonstrate a change in their ROS generation or NF-kappa B binding activity or plasma CRP concentration. We conclude that valsartan at a modest dose exerts a profound and rapid ROS and inflammation-suppressive effect that may be relevant to its potential beneficial effects in atherosclerosis, diabetes, and congestive cardiac failure. In contrast, quinapril and simvastatin produced no similar effect over the period of 1 wk. Our observations may also have implications to clinical situations in which a rapid antiinflammatory effect is required.
鉴于血管紧张素II的促氧化和促炎作用,我们检验了以下假设:血管紧张素受体阻滞剂缬沙坦可能对单核细胞中的活性氧(ROS)生成、核因子κB(NF-κB)发挥抑制作用。四组,每组八名正常受试者,分别给予:1)每日160毫克缬沙坦;2)每日80毫克辛伐他汀;3)40毫克喹那普利;4)不进行治疗。在治疗前以及第1、8和14天(停药7天后)采集空腹血样。服用缬沙坦后,多形核细胞和单核细胞的ROS生成显著下降超过40%(P<0.01)。NF-κB结合活性以及NF-κB的蛋白质成分总细胞p65的表达显著下降(P<0.01)。抑制蛋白κB(IκB)的表达显著增加(P<0.05)。血浆C反应蛋白(CRP)浓度显著下降(P<0.01)。停药7天后,除IκB外,所有指标均恢复至基线水平。IκB持续处于升高状态。给予喹那普利或辛伐他汀7天均未抑制ROS生成、核内NF-κB、p65或CRP,且这两种药物也未改变细胞IκB。未治疗的对照组在ROS生成、NF-κB结合活性或血浆CRP浓度方面也未显示出变化。我们得出结论,中等剂量的缬沙坦具有显著且快速的ROS和炎症抑制作用,这可能与其在动脉粥样硬化、糖尿病和充血性心力衰竭中的潜在有益作用相关。相比之下,喹那普利和辛伐他汀在1周内未产生类似效果。我们的观察结果可能也适用于需要快速抗炎作用的临床情况。